Different Surgical Approaches for Managing Prosthetic Joint Infection (PJI): Indications and Implications

Different Surgical Approaches for Managing Prosthetic Joint Infection (PJI): Indications and Implications

High-Yield Executive Summary

• Early vs. late PJI dictates surgical strategy: Acute infections (<3-4 weeks) may be amenable to debridement, antibiotics, and implant retention (DAIR), while chronic infections typically require implant removal and staged revision.
• Classification systems (Tsukayama, Zimmerli) guide timing and approach: Accurate classification of infection onset and biofilm maturity is critical for selecting DAIR, one-stage, or two-stage revision.
• One-stage revision offers comparable infection control with faster recovery but requires strict patient selection: Ideal for known pathogens with good soft tissue and bone stock.
• Two-stage revision remains the gold standard for complex, resistant, or culture-negative infections: Allows thorough eradication but at the cost of prolonged disability.
• Surgical success hinges on meticulous debridement, implant removal, and appropriate antibiotic delivery: Intraoperative red flags include persistent purulence, compromised soft tissue, and biofilm presence.

Clinical Fundamentals

Anatomy & Biomechanics:
PJI most commonly affects the hip and knee prostheses, where the joint capsule, synovium, and periprosthetic bone interface are critical. Biofilm formation on implant surfaces shields bacteria from host immunity and antibiotics, complicating eradication. Understanding the vascular supply to periprosthetic tissues guides debridement extent and soft tissue management.

Epidemiology:
PJI incidence ranges from 1-2% in primary arthroplasty, rising to 4-6% in revisions. Risk factors include immunosuppression, diabetes, prior infection, and prolonged operative time. Early infections often result from intraoperative contamination; late infections may arise hematogenously.

Classification & Diagnosis

Classification Systems:

• Tsukayama Classification:
• Type I: Early postoperative (<1 month)
• Type II: Late chronic (>1 month)
• Type III: Acute hematogenous
• Type IV: Positive intraoperative cultures without clinical infection

• Zimmerli Classification:
• Early (<3 weeks)
• Delayed (3 weeks to 3 months)
• Late (>3 months)

Diagnostic Pearls:

• Synovial fluid analysis (WBC >3000/?L, PMN% >80%) is highly sensitive.
• Alpha-defensin and leukocyte esterase tests improve rapid diagnosis.
• Multiple tissue cultures (?3-5 samples) increase yield; avoid false negatives by withholding antibiotics preoperatively.
• Imaging (nuclear scans, MRI) is adjunctive, not definitive.

Common Pitfalls:

• Misclassifying chronic infections as acute leads to failed DAIR.
• Overreliance on serum markers (ESR, CRP) without clinical correlation.
• Ignoring biofilm maturity and pathogen virulence in surgical planning.

The Decision-Making Algorithm

Non-Operative vs. Operative Management:

• Non-operative management is rarely curative; reserved for non-ambulatory or high-risk patients.
• Operative intervention is standard for all confirmed PJIs.

Surgical Approach Selection:

Why these choices?
DAIR preserves the implant but requires early intervention before biofilm maturation. One-stage revision balances infection control and function but demands stringent criteria. Two-stage revision maximizes eradication but prolongs morbidity.

Surgical Mastery & Pearls

DAIR Procedure:

1. Exposure: Use previous incision; avoid new soft tissue planes.
2. Aggressive Debridement: Remove all necrotic tissue, synovectomy, and exchange modular components (liners, heads).
3. Irrigation: Pulsatile lavage with copious saline; consider antiseptic solutions cautiously.
4. Implant Retention: Only if stable and well-fixed.
5. Intraoperative Cultures: Obtain multiple samples before antibiotics.
6. Red Flags: Persistent purulence after debridement, implant loosening, or sinus tract mandates implant removal.

One-Stage Revision:

1. Complete Implant Removal: Meticulous extraction of all components.
2. Extensive Debridement: Remove all infected and devitalized tissue.
3. Immediate Reimplantation: Use antibiotic-loaded cement tailored to culture sensitivities.
4. Soft Tissue Management: Ensure tension-free closure; consider plastic surgery if needed.
5. Red Flags: Uncertain pathogen, poor soft tissue, or bone loss contraindicate this approach.

Two-Stage Revision:

1. First Stage: Remove all implants, aggressive debridement, place antibiotic spacer.
2. Interim Period: Systemic antibiotics guided by cultures, monitor inflammatory markers.
3. Second Stage: Reimplantation after infection eradication confirmed clinically and biochemically.
4. Red Flags: Persistent elevated markers or clinical signs delay reimplantation.

Evidence-Based Synthesis

• DAIR efficacy is highest when performed within 3-4 weeks of symptom onset; success rates vary from 60-80%. Recent meta-analyses emphasize early intervention and modular component exchange as critical factors.
• One-stage revision has gained traction, especially in Europe, with randomized trials showing non-inferior infection control and superior functional outcomes compared to two-stage revision in selected patients (e.g., known pathogen, good soft tissue). However, heterogeneity in patient selection limits universal adoption.
• Two-stage revision remains the benchmark for complex infections, with infection eradication rates >90%. Recent studies focus on optimizing spacer design and antibiotic regimens to reduce morbidity.
• Biofilm-targeted strategies and local antibiotic delivery (e.g., high-dose antibiotic cement, spacers) are supported by in vitro and clinical data but require further standardization.
• Controversies persist regarding the optimal timing of reimplantation, duration of antibiotics, and management of culture-negative infections, highlighting the need for individualized care.

Pro-Tip: Surgical Excellence in PJI Management

• Master the timing: Early recognition and classification of PJI are paramount; delays convert manageable infections into complex cases.
• Modular component exchange during DAIR is non-negotiable: Retaining liners or heads compromises biofilm removal.
• Tailor antibiotic cement formulations intraoperatively: Collaborate closely with infectious disease specialists to optimize local and systemic therapy.
• Soft tissue is king: Prioritize soft tissue viability and closure; consider plastic surgery early in complex cases to prevent reinfection.
• Intraoperative vigilance: If implant loosening or extensive purulence is encountered unexpectedly during DAIR, convert to implant removal without hesitation.
• Document meticulously: Clear operative notes on debridement extent, tissue quality, and intraoperative findings guide postoperative management and future interventions.

This synthesis equips orthopaedic trainees with a focused, evidence-driven framework to approach PJI surgically, emphasizing decision-making precision and technical mastery essential for optimizing patient outcomes.

Last Updated on January 26, 2026 by OrthoNet AI